Demonstration of feasibility of a novel agglomerated raw material
Lead Participant:
CHRYSALIS HEALTH & BEAUTY BUSINESS SOLUTIONS LTD
Abstract
Chrysalis, a UK-based SME, intends to develop several new, innovative added-value product
lines for the food, food supplement and pharmaceutical markets based on the novel
application of experimental agglomeration technologies to food-waste products.
Chrysalis’ is seeking to test the feasibility of this approach by developing an agglomerated
calcium carbonate (ACC) from UK sourced waste chicken egg shells, 15,000 tonnes of which
are sent to landfill/yr.
Calcium carbonate is both a cost-effective source of calcium and a bulking agent used in food
supplements and fortified foods. These products are increasingly popular as many consumers
typically don’t receive enough calcium (RDI 800mg) from dietary sources, which can lead to
an increased risk of osteoporosis.
Although its affordability and processing properties have made calcium carbonate highly
desirable to manufacturers, current inorganic sources suffer from quality, environmental and
reliability issues that have led to recalls and consumer complaints, creating market demand for
a credible alternative.
Chrysalis plans to use novel agglomeration techniques and processing aids to develop a
sustainable, viable alternative from UK egg shells that can directly replace existing raw
materials without negatively impacting consumer product characteristics. Egg shells make an
appealing source as they’re a very concentrated, highly absorbable form of dietary calcium, a
neutral colour / taste and relatively low cost.
In the proposed project, Chrysalis will seek to confirm the technical feasibility of using novel
agglomeration methodologies to develop a sustainably sourced ACC that can ‘drop-in’ to
existing processes, providing benefits to manufacturers and consumers, including improved
product quality and palatability.
Conditional on project outputs, Chrysalis are seeking to establish a platform technology that
can potentially be adapted to other novel raw material sources for both food and
pharmaceutical applications.
lines for the food, food supplement and pharmaceutical markets based on the novel
application of experimental agglomeration technologies to food-waste products.
Chrysalis’ is seeking to test the feasibility of this approach by developing an agglomerated
calcium carbonate (ACC) from UK sourced waste chicken egg shells, 15,000 tonnes of which
are sent to landfill/yr.
Calcium carbonate is both a cost-effective source of calcium and a bulking agent used in food
supplements and fortified foods. These products are increasingly popular as many consumers
typically don’t receive enough calcium (RDI 800mg) from dietary sources, which can lead to
an increased risk of osteoporosis.
Although its affordability and processing properties have made calcium carbonate highly
desirable to manufacturers, current inorganic sources suffer from quality, environmental and
reliability issues that have led to recalls and consumer complaints, creating market demand for
a credible alternative.
Chrysalis plans to use novel agglomeration techniques and processing aids to develop a
sustainable, viable alternative from UK egg shells that can directly replace existing raw
materials without negatively impacting consumer product characteristics. Egg shells make an
appealing source as they’re a very concentrated, highly absorbable form of dietary calcium, a
neutral colour / taste and relatively low cost.
In the proposed project, Chrysalis will seek to confirm the technical feasibility of using novel
agglomeration methodologies to develop a sustainably sourced ACC that can ‘drop-in’ to
existing processes, providing benefits to manufacturers and consumers, including improved
product quality and palatability.
Conditional on project outputs, Chrysalis are seeking to establish a platform technology that
can potentially be adapted to other novel raw material sources for both food and
pharmaceutical applications.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| CHRYSALIS HEALTH & BEAUTY BUSINESS SOLUTIONS LTD | £165,689 | £ 99,413 |
People |
ORCID iD |